{"disease":{"id":"tumor-induced-osteomalacia-tio","name":"tumor induced osteomalacia tio"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04783428","title":"Tumor-induced Osteomalacia Disease Monitoring Program","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false},{"nct_id":"NCT02304367","title":"Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Kyowa Kirin, Inc.","has_results":true},{"nct_id":"NCT05357573","title":"Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}